TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22983502

Group type: EXPERIMENTAL
Intervention: Exchange sex (>=1 exchange sex partner, past 90 days) among female NIDUs
Number of subjects: 417

Group type: EXPERIMENTAL
Intervention: Strengthening ties that provide social support but not drug support
Number of subjects: 417

Group type: EXPERIMENTAL
Intervention: Reducing ties that provide both drug and social support
Number of subjects: 417
Study: 21458015

Group type: EXPERIMENTAL
Intervention: Specialized training course for single-port laparoscopic surgery
Number of subjects: 10

Group type: COMPARATOR
Intervention: Traditional training course for laparoscopy basic skills
Number of subjects: 10
Study: 18065204

Group type: EXPERIMENTAL
Intervention: Gln-supplemented PN (Gln-PN)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Standard PN (Gln-free)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Both interventions (Gln-PN and Standard PN)
Number of subjects: 59
Study: 17045558

Group type: EXPERIMENTAL
Intervention: Six-dose regimen of artemether-lumefantrine
Number of subjects: 1368
Study: 12938592

Group type: EXPERIMENTAL
Intervention: Patient controlled intravenous morphine
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Epidural morphine
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Non-steroidal anti-inflammatory drugs
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Intravenous morphine
Number of subjects: 80
Study: 10716474

Group type: COMPARATOR
Intervention: L-arginine (8 g/day)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Training group (daily handgrip training)
Number of subjects: 40

Group type: COMPARATOR
Intervention: L-arginine + Training
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Control group (inactive)
Number of subjects: 40
Study: 9366938

Group type: EXPERIMENTAL
Intervention: Granisetron 20 micrograms.kg-1
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Granisetron 40 micrograms.kg-1
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Granisetron 80 micrograms.kg-1
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 120
Study: 1490801

Group type: EXPERIMENTAL
Intervention: Trapidil (200 mg orally, 100 mg intravenously)
Number of subjects: 15
Study: 3987781

Group type: EXPERIMENTAL
Intervention: Nifedipine (10 mg) before standardized breakfast (Phase A)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Nifedipine (10 mg) after standardized breakfast (Phase B)
Number of subjects: 10
Study: 30601920

Group type: EXPERIMENTAL
Intervention: Acetazolamide 250 mg twice daily
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Acetazolamide
Number of subjects: 20
Study: 28671938

Group type: EXPERIMENTAL
Intervention: Cardiac Rehabilitation (CR) for hospitalized patients with HFrEF
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Cardiac Rehabilitation (CR) for stable outpatients with HFrEF
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Cardiac Rehabilitation (CR) for total cohort
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Cardiac Rehabilitation (CR) for those who completed CR
Number of subjects: 119
Study: 26743070

Group type: EXPERIMENTAL
Intervention: Contact force monitoring during catheter ablation
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (no contact force monitoring)
Number of subjects: 28
Study: 24747978

Group type: EXPERIMENTAL
Intervention: Quetiapine XR
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 22067765

Group type: EXPERIMENTAL
Intervention: Contraceptive vaginal ring (CVR)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Norethisterone
Number of subjects: 95
Study: 19643646

Group type: EXPERIMENTAL
Intervention: Intervention participants (two 4-hr group sessions)
Number of subjects: 170

Group type: COMPARATOR
Intervention: Control participants (2-hr session on healthy nutrition)
Number of subjects: 170
Study: 18781148

Group type: EXPERIMENTAL
Intervention: Control Preferences Scale (CPS)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Clinician views on patient participation
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Patient views on participation
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: General views on participation
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: General views on clinician ability
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Clinician reluctance
Number of subjects: 130
Study: 15631889

Group type: EXPERIMENTAL
Intervention: ZDHHC8 SNP (rs175174)
Number of subjects: 1090

Group type: COMPARATOR
Intervention: Control group (529 individuals)
Number of subjects: 1090
Study: 12357163

Group type: EXPERIMENTAL
Intervention: Continuous thoracic epidural blockade with local anesthetic and opioid
Number of subjects: 16

Group type: COMPARATOR
Intervention: Patient-controlled intravenous analgesia with morphine
Number of subjects: 16
Study: 10490854

Group type: EXPERIMENTAL
Intervention: L‐dopa
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 9772584

Group type: EXPERIMENTAL
Intervention: Zusanli point immunotherapy (ZPIT)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Conventional desensitization therapy
Number of subjects: 69

Group type: COMPARATOR
Intervention: Injected normal saline
Number of subjects: 69
Study: 1929138

Group type: EXPERIMENTAL
Intervention: Short-term drainage (drain removed after 5 days)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Standard drainage (drain removed when fluid was less than 20 ml per day)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Short-term drainage
Number of subjects: 84

Group type: COMPARATOR
Intervention: Standard drainage
Number of subjects: 84
Study: 6812337

Group type: EXPERIMENTAL
Intervention: Clebopride 1 mg orally at 24.00 h
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Clebopride 1 mg orally at 09.00 h
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo at 24.00 h
Number of subjects: 10
Study: 30763755

Group type: EXPERIMENTAL
Intervention: Citicoline treatment
Number of subjects: 0
Study: 28660720

Group type: EXPERIMENTAL
Intervention: Prednisolone for 3 days
Number of subjects: 79

Group type: COMPARATOR
Intervention: Placebo for 3 days
Number of subjects: 79
Study: 25028414

Group type: EXPERIMENTAL
Intervention: Intravenous baclofen (3 mg and 5 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Oral baclofen (5 mg and 10 mg)
Number of subjects: 12
Study: 23872994

Group type: EXPERIMENTAL
Intervention: Brief two-session counselor-delivered computer-tailored intervention
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 120
Study: 20605840

Group type: EXPERIMENTAL
Intervention: Thr/Ser and Ser/Ser genotype
Number of subjects: 1043

Group type: EXPERIMENTAL
Intervention: Fetuin-A levels
Number of subjects: 1043

Group type: EXPERIMENTAL
Intervention: Inflammation and diabetes
Number of subjects: 1043
Study: 19901165

Group type: EXPERIMENTAL
Intervention: Interferon beta‐1b (3 years)
Number of subjects: 468

Group type: COMPARATOR
Intervention: Placebo followed by interferon beta‐1b (> or = 1 year)
Number of subjects: 468

Group type: EXPERIMENTAL
Intervention: Baseline presence of at least 9 T2-weighted lesions
Number of subjects: 468

Group type: EXPERIMENTAL
Intervention: Baseline presence of at least 3 periventricular lesions
Number of subjects: 468

Group type: EXPERIMENTAL
Intervention: Using a fixed cutoff of at least 3 Barkhof criteria
Number of subjects: 468

Group type: EXPERIMENTAL
Intervention: Dissemination in time at 9-month MR imaging
Number of subjects: 468
Study: 17020437

Group type: EXPERIMENTAL
Intervention: Osmotic, controlled-release methylphenidate (OROS MPH)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Immediate-release methylphenidate (IR MPH) dosed three times daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Non-stimulant treatments (e.g., atomoxetine)
Number of subjects: 0
Study: 14769594

Group type: EXPERIMENTAL
Intervention: Latanoprost (0.005%) once daily
Number of subjects: 30

Group type: COMPARATOR
Intervention: Timolol (0.5%) twice daily
Number of subjects: 30
Study: 11233547

Group type: EXPERIMENTAL
Intervention: Subdermal injection
Number of subjects: 80

Group type: COMPARATOR
Intervention: Peritumoural injection
Number of subjects: 80
Study: 9000414

Group type: EXPERIMENTAL
Intervention: Gadolinium-ethoxybenzyl-DTPA (Gd-EOB-DTPA) 10 micromol/kg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Gadolinium-ethoxybenzyl-DTPA (Gd-EOB-DTPA) 25 micromol/kg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Gadolinium-ethoxybenzyl-DTPA (Gd-EOB-DTPA) 50 micromol/kg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Gadolinium-ethoxybenzyl-DTPA (Gd-EOB-DTPA) 100 micromol/kg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Gadolinium-ethoxybenzyl-DTPA (Gd-EOB-DTPA)
Number of subjects: 16
Study: 8130709

Group type: EXPERIMENTAL
Intervention: Brief nurse‐administered anti‐smoking intervention
Number of subjects: 751

Group type: EXPERIMENTAL
Intervention: Intention to stop smoking
Number of subjects: 751

Group type: EXPERIMENTAL
Intervention: Sustained cessation
Number of subjects: 751

Group type: EXPERIMENTAL
Intervention: Social variables (e.g., marital status, time spent with smokers)
Number of subjects: 751
Study: 3298071

Group type: EXPERIMENTAL
Intervention: Acyclovir (800 mg, two 400 mg tablets, five times daily for seven days)
Number of subjects: 205

Group type: COMPARATOR
Intervention: Placebo (matching placebo, five times daily for seven days)
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Acyclovir
Number of subjects: 205

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 205
Study: 30922004

Group type: EXPERIMENTAL
Intervention: Group A (excellent clinical efficacy)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Group B (good clinical efficacy)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Group C (poor clinical efficacy)
Number of subjects: 0
Study: 28259273

Group type: EXPERIMENTAL
Intervention: Minocycline (200 mg orally 2 hours prior to procedure, then 100 mg twice a day for 5 days)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Placebo (oral placebo 2 hours prior to procedure, then placebo twice a day for 5 days)
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Minocycline (in subgroup with elevated posttraumatic distress scores)
Number of subjects: 131
Study: 26342502

Group type: EXPERIMENTAL
Intervention: Oral ivermectin 200 μg/kg body weight
Number of subjects: 420

Group type: COMPARATOR
Intervention: Sulfur 10% ointment applied for three successive days
Number of subjects: 420
Study: 23963058

Group type: EXPERIMENTAL
Intervention: Fluoxetine (10 mg twice daily)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Calcium carbonate (600 mg twice daily)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 21654688

Group type: EXPERIMENTAL
Intervention: Irinotecan at starting doses of 180 mg m(‐2) for *1/*1, 110 mg m(‐2) for *1/*28, and 90 mg m(‐2) for *28/*28 genotypes; escalated to 450 mg m(‐2) for *1/*1, 390 mg m(‐2) for *1/*28, and 150 mg m(‐2) for *28/*28 genotypes.
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Recommended dose of 180 mg m(‐2) for irinotecan in FOLFIRI.
Number of subjects: 94
Study: 19047225

Group type: EXPERIMENTAL
Intervention: Oral ibuprofen
Number of subjects: 64

Group type: COMPARATOR
Intervention: Intravenous ibuprofen
Number of subjects: 64
Study: 16929435

Group type: EXPERIMENTAL
Intervention: Computer-assisted navigation technique
Number of subjects: 36

Group type: COMPARATOR
Intervention: Conventional approach
Number of subjects: 36
Study: 15179649

Group type: EXPERIMENTAL
Intervention: Intra-articular injections of hyaluronate (5 weekly injections)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Intra-articular injections of hyaluronate
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group (non-OA subjects)
Number of subjects: 15
Study: 11431435

Group type: EXPERIMENTAL
Intervention: 1% tropicamide
Number of subjects: 469
Study: 9751463

Group type: EXPERIMENTAL
Intervention: Oral glucocorticoid treatment
Number of subjects: 0
Study: 7516979

Group type: EXPERIMENTAL
Intervention: Active treatment (transurethral microwave therapy)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Active treatment (transurethral microwave therapy) after sham treatment
Number of subjects: 40
Study: 3190622

Group type: COMPARATOR
Intervention: 2 mg dexamethasone orally every 6 h (starting 1 h before take-off)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: 4 mg dexamethasone orally or intramuscularly every 6 h for 24 h
Number of subjects: 26
Study: 31556690

Group type: EXPERIMENTAL
Intervention: Aroma comprising a mixture of Lavandula x intermedia (Lavandin Super), Citrus bergamia (bergamot), and Cananga odorata (ylang ylang)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 28401564

Group type: EXPERIMENTAL
Intervention: 50 mg naltrexone daily for 10 weeks
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo daily for 10 weeks
Number of subjects: 150
Study: 26846078

Group type: EXPERIMENTAL
Intervention: G-immunochemical MM patients with infections (Group 1)
Number of subjects: 101

Group type: COMPARATOR
Intervention: G-immunochemical MM patients without infections (Group 2)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Healthy volunteers (Group 3)
Number of subjects: 101
Study: 23419135

Group type: EXPERIMENTAL
Intervention: Combined risk expression format (frequency and percentage)
Number of subjects: 129

Group type: COMPARATOR
Intervention: Percentage format (e.g. 'affects 25% of people')
Number of subjects: 129

Group type: COMPARATOR
Intervention: Frequency format (e.g. 'affects 1 in 4 people')
Number of subjects: 129
Study: 21205874

Group type: EXPERIMENTAL
Intervention: Metformin (2 g daily)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Repaglinide (6 mg daily)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Both treatments (Metformin and Repaglinide)
Number of subjects: 96
Study: 19888336

Group type: EXPERIMENTAL
Intervention: Wireless Tongue Display Unit (TDU) biofeedback system
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (no biofeedback)
Number of subjects: 24
Study: 16534885

Group type: EXPERIMENTAL
Intervention: Intravenous cyclophosphamide (800 mg) per month for 6 cycles
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Methotrexate (15 mg/wk) for Crohn's disease patients
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Azathioprine (2.5 mg/kg body weight/d) for ulcerative colitis patients
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Overall treatment with cyclophosphamide
Number of subjects: 8
Study: 12883972

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCTZ)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 10960944

Group type: EXPERIMENTAL
Intervention: PGV (cisplatin, gemcitabine, vinorelbine)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: PG (cisplatin, gemcitabine)
Number of subjects: 240

Group type: COMPARATOR
Intervention: PV (cisplatin, vinorelbine)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: PGT (cisplatin, gemcitabine, paclitaxel)
Number of subjects: 240
Study: 9295453

Group type: EXPERIMENTAL
Intervention: Individual education program with arthritis passport
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Educational materials only
Number of subjects: 3

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Coordination of care with arthritis passport
Number of subjects: 3
Study: 8040707

Group type: EXPERIMENTAL
Intervention: Baking soda/hydrogen peroxide dentifrice (Mentadent)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 0.12 percent chlorhexidine gluconate mouthrinse (Peridex)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (standard oral hygiene)
Number of subjects: 40
Study: 3541623

Group type: EXPERIMENTAL
Intervention: 3 mg of percutaneous estradiol
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Oral micronized progesterone (200 mg) for 12 days of each cycle during the second year
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: End of study period
Number of subjects: 45
Study: 29400621

Group type: EXPERIMENTAL
Intervention: Integrative body-mind-spirit intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cognitive behavioral therapy
Number of subjects: 0
Study: 27534634

Group type: EXPERIMENTAL
Intervention: SQ-LNS group
Number of subjects: 1228

Group type: COMPARATOR
Intervention: IFA group
Number of subjects: 1228

Group type: COMPARATOR
Intervention: MMN group
Number of subjects: 1228

Group type: EXPERIMENTAL
Intervention: Actual supplement provided (LNS)
Number of subjects: 1228

Group type: COMPARATOR
Intervention: Actual supplement provided (IFA)
Number of subjects: 1228

Group type: COMPARATOR
Intervention: Actual supplement provided (MMN)
Number of subjects: 1228
Study: 25907407

Group type: EXPERIMENTAL
Intervention: Cabozantinib with a high-fat meal (study 1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cabozantinib with esomeprazole (study 2)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cabozantinib alone (study 2)
Number of subjects: 0
Study: 23953553

Group type: EXPERIMENTAL
Intervention: Everolimus with reduced cyclosporine (CsA)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Mycophenolate mofetil (MMF) with reduced cyclosporine (CsA)
Number of subjects: 70
Study: 20564081

Group type: EXPERIMENTAL
Intervention: Cytoreductive surgery combined with hyperthermic intraperitoneal chemoperfusion (n=67)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Systemic chemotherapy alone (Control group, n=38)
Number of subjects: 105
Study: 18784322

Group type: EXPERIMENTAL
Intervention: Intervention with mothers and fathers included in the breastfeeding education program
Number of subjects: 586

Group type: COMPARATOR
Intervention: Intervention with only mothers exposed to the breastfeeding education program
Number of subjects: 586

Group type: EXPERIMENTAL
Intervention: Intervention with fathers with less than 8 years of schooling
Number of subjects: 586
Study: 16018426

Group type: EXPERIMENTAL
Intervention: Minocycline-EDTA
Number of subjects: 60

Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 60
Study: 14506579

Group type: EXPERIMENTAL
Intervention: Fascicular transfer
Number of subjects: 7

Group type: COMPARATOR
Intervention: End-to-side nerve coaptation
Number of subjects: 7
Study: 11076110

Group type: EXPERIMENTAL
Intervention: Sevelamer hydrochloride treated patients
Number of subjects: 152

Group type: COMPARATOR
Intervention: Control group (non-sevelamer treated patients)
Number of subjects: 152
Study: 8866042

Group type: COMPARATOR
Intervention: Flurbiprofen (200 mg multiple-unit sustained release capsule) after overnight fast
Number of subjects: 38

Group type: COMPARATOR
Intervention: Ibuprofen (800 mg erodible sustained release matrix tablet) after overnight fast
Number of subjects: 38
Study: 1507928

Group type: EXPERIMENTAL
Intervention: 5 mg magnesium‐DL‐hydrogen aspartate
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: magnesium‐L‐hydrogen aspartate
Number of subjects: 18
Study: 6653132

Group type: EXPERIMENTAL
Intervention: 0.5 mg flunitrazepam
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 1 mg flunitrazepam
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 2 mg flunitrazepam
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 31724337

Group type: EXPERIMENTAL
Intervention: dl-3-n-butylphthalide (NBP), 100 ml administered by intravenous injection, 2 times/day for 14 days
Number of subjects: 136

Group type: COMPARATOR
Intervention: Routine drug therapy (Control)
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: dl-3-n-butylphthalide (NBP)
Number of subjects: 136
Study: 30396363

Group type: COMPARATOR
Intervention: Medetomidine (3.0 μg/kg/h)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Medetomidine (3.0 μg/kg/h) and Propofol (3.0 mg/kg/h)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Medetomidine (3.0 μg/kg/h) and Propofol (6.0 mg/kg/h)
Number of subjects: 30
Study: 26708017

Group type: EXPERIMENTAL
Intervention: MI + CBT (n = 26)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: NDC + CBT (n = 26)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Waitlist Control (WC, n = 23)
Number of subjects: 75
Study: 24818209

Group type: EXPERIMENTAL
Intervention: Immediate loading
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional loading (Control)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Postoperative pain/swelling
Number of subjects: 30
Study: 23114104

Group type: EXPERIMENTAL
Intervention: Nevirapine prophylaxis (SWEN)
Number of subjects: 737

Group type: EXPERIMENTAL
Intervention: HIV-infected infants
Number of subjects: 737

Group type: EXPERIMENTAL
Intervention: HIV-uninfected infants
Number of subjects: 737

Group type: COMPARATOR
Intervention: Baseline prevalence
Number of subjects: 737

Group type: EXPERIMENTAL
Intervention: Timing of HIV infection
Number of subjects: 737
Study: 19874329

Group type: EXPERIMENTAL
Intervention: Levothyroxine plus 5 mg/day desloratadine (suppression group, n = 8)
Number of subjects: 15

Group type: COMPARATOR
Intervention: 5 mg/day desloratadine alone (control group, n = 7)
Number of subjects: 15
Study: 17585215

Group type: EXPERIMENTAL
Intervention: Airtraq laryngoscope
Number of subjects: 40

Group type: COMPARATOR
Intervention: Macintosh laryngoscope
Number of subjects: 40
Study: 16232342

Group type: EXPERIMENTAL
Intervention: Early extubation and noninvasive MV via facial mask immediately after PIC window
Number of subjects: 90

Group type: COMPARATOR
Intervention: Invasive MV received continuously after PIC window by using conventional weaning technique
Number of subjects: 90
Study: 12011967

Group type: EXPERIMENTAL
Intervention: HR (Paroven, Venoruton; 0-(beta-hydroxyethyl)-rutosides) 1 g, twice daily for 6 months
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: COMPARATOR
Intervention: Healthy subjects
Number of subjects: 20
Study: 10930636

Group type: EXPERIMENTAL
Intervention: Tramadol 0.5 mg kg(‐1)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Tramadol 1 mg kg(‐1)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 9420536

Group type: EXPERIMENTAL
Intervention: Topical PUVA (n = 28)
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: 311-nm UV-B radiation (n = 78)
Number of subjects: 281

Group type: COMPARATOR
Intervention: 311-nm UV-B radiation (n = 60, followed for 3 months)
Number of subjects: 281

Group type: COMPARATOR
Intervention: 311-nm UV-B radiation (n = 51, followed for 12 months)
Number of subjects: 281